Blackstone Life Sciences

Blackstone Life Sciences is a premier investment platform within Blackstone dedicated to funding and advancing innovations in the healthcare and life sciences sectors. Established in 2018 following the acquisition of Clarus, the firm manages one of the largest private life sciences investment funds globally. It specializes in late-stage clinical development, providing capital through R&D collaborations, royalty acquisitions, and the formation of new biotechnology companies. By partnering with leading pharmaceutical and biotech firms, Blackstone Life Sciences helps accelerate the delivery of transformative medicines to market. Their portfolio includes significant investments in therapies for cardiovascular disease, oncology, and rare diseases.